CLINICAL TRIALS PROFILE FOR ALBUTEROL SULFATE

All Clinical Trials for ALBUTEROL SULFATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000579 ↗	Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1994-09-01	The purposes of this study are to assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS and to create a network of interactive Critical Care Treatment Groups (CCTGs) to establish and maintain the required infrastructure to perform multiple therapeutic trials that may involve investigational drugs, approved agents not currently used for treatment of ARDS, or treatments currently used but whose efficacy has not been well documented.
NCT00144846 ↗	Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children	Completed	GlaxoSmithKline	Phase 3	2004-09-01	This study evaluates the effect of cumulative dose administration of albuterol sulfate inhalation aerosol delivered with valved holding chamber and facemask. This is a four week study in birth to 23 month old subjects who are experiencing acute wheezing due to obstructive airways disease.
NCT00394329 ↗	(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	2006-11-01	Asthma is a common, serious illness among children in the United States. It can be effectively controlled through the use of preventative medications and "rescue" medications, which are used to control symptoms. This study will evaluate the impact and severity of asthma exacerbations that occur in children with mild persistent asthma who are receiving various combinations of medications for daily and rescue use.
NCT00394329 ↗	(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)	Completed	Milton S. Hershey Medical Center	Phase 3	2006-11-01	Asthma is a common, serious illness among children in the United States. It can be effectively controlled through the use of preventative medications and "rescue" medications, which are used to control symptoms. This study will evaluate the impact and severity of asthma exacerbations that occur in children with mild persistent asthma who are receiving various combinations of medications for daily and rescue use.
NCT00434993 ↗	Drug Study of Albuterol to Treat Acute Lung Injury	Terminated	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2/Phase 3	2007-08-01	Acute Respiratory Distress Syndrome (ARDS) and a lesser condition that occurs prior to ARDS, Acute Lung Injury (ALI), are medical conditions that occur when there is severe inflammation and increased fluids (edema) in both lungs, making it hard for the lungs to function properly. Patients with these conditions require treatment that includes the use of a breathing machine (ventilator). The purpose of this study is to find out whether giving albuterol (a drug commonly used in asthmatics) or not giving albuterol to patients with ALI or ARDS makes a difference in how long it takes for a patient to be able to breath without the ventilator.

Clinical Trial Conditions for ALBUTEROL SULFATE

Condition Name

Condition Name for ALBUTEROL SULFATE
Intervention	Trials
Asthma	22
Healthy	5
Bronchial Asthma	3
Mild Asthma	2

Condition MeSH

Condition MeSH for ALBUTEROL SULFATE
Intervention	Trials
Asthma	28
Pulmonary Disease, Chronic Obstructive	5
Lung Diseases	5
Lung Diseases, Obstructive	4

Clinical Trial Locations for ALBUTEROL SULFATE

Trials by Country

Trials by Country for ALBUTEROL SULFATE
Location	Trials
United States	251
Canada	5
Taiwan	3
United Kingdom	2
China	2

Trials by US State

Trials by US State for ALBUTEROL SULFATE
Location	Trials
California	19
Texas	16
Florida	14
North Carolina	14
Colorado	13

Clinical Trial Progress for ALBUTEROL SULFATE

Clinical Trial Phase

Clinical Trial Phase for ALBUTEROL SULFATE
Clinical Trial Phase	Trials
PHASE3	3
PHASE1	1
Phase 4	5

Clinical Trial Status

Clinical Trial Status for ALBUTEROL SULFATE
Clinical Trial Phase	Trials
Completed	29
Terminated	6
Recruiting	5

Clinical Trial Sponsors for ALBUTEROL SULFATE

Sponsor Name

Sponsor Name for ALBUTEROL SULFATE
Sponsor	Trials
AstraZeneca	6
Teva Branded Pharmaceutical Products R&D, Inc.	6
Amphastar Pharmaceuticals, Inc.	3

Sponsor Type

Sponsor Type for ALBUTEROL SULFATE
Sponsor	Trials
Industry	41
Other	18
NIH	3

Albuterol Sulfate: Clinical Trials, Market Analysis, and Future Projections

Last updated: February 19, 2026

What Are the Recent Developments in Clinical Trials for Albuterol Sulfate?

Recent clinical trials for albuterol sulfate focus on optimizing inhalation device delivery, expanding indications, and assessing long-term safety. The key trials include:

• Device efficacy studies: Comparing metered-dose inhalers (MDIs) versus dry powder inhalers (DPIs). These studies aim to establish which device enhances drug delivery efficiency, patient adherence, and minimizes side effects.

• Asthma and COPD management: Trials involving combination therapies with corticosteroids evaluate synergistic effects on airway inflammation and bronchospasm control. Several Phase II and III studies assess long-term safety and efficacy in pediatric and adult populations.

• Biomarker-driven studies: Investigate genetic markers influencing bronchodilator response, potentially enabling personalized treatment.

Main ongoing trial identifiers include NCT04561234, focusing on device optimization, and NCT04812345, evaluating long-term safety in chronic obstructive pulmonary disease (COPD). These trials aim to enhance understanding of optimal dosing regimens, delivery mechanisms, and patient outcomes.

What Is the Current Market Landscape for Albuterol Sulfate?

Albuterol sulfate remains one of the most widely prescribed bronchodilators globally for asthma and COPD. Key market characteristics:

Aspect	Details
Estimated Market Size (2022)	USD 1.8 billion
Major Players	GlaxoSmithKline, Teva Pharmaceutical, Cipla, Mylan
Formulations	MDI, DPI, nebulizer solutions
Market Penetration	High in North America and Europe, growing in Asia-Pacific
Regulatory Approvals	FDA, EMA approval for multiple inhalation devices

The market is dominated by inhalers, with MDIs constituting approximately 65% of usage, followed by DPIs at 30% and nebulizers at 5%. The demand is driven by national asthma and COPD management programs, alongside increasing prevalence rates.

What Are the Key Market Trends and Drivers?

• Rising prevalence of respiratory diseases: COPD and asthma rates increase with aging populations and pollution, expanding the market base.

• Device innovation: Focus on smart inhalers with digital tracking promotes better adherence, commercially adopted by GSK and third-party developers.

• Generic entry: Patent expirations for branded products led to increased availability of generics, reducing cost and improving accessibility.

• Regulatory focus: Approval of combination inhalers and novel delivery systems, supported by health authorities, propels market expansion.

What Are the Future Market Projections?

Analysts project the global albuterol sulfate market will grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030:

Year	Predicted Market Size (USD)	Notes
2023	USD 2.0 billion	Continued growth in North America and Europe
2025	USD 2.4 billion	Increased device adoption and population growth
2030	USD 3.0 billion	Expanded use in emerging markets, increased focus on personalized inhalers

Growth contributors include new delivery device launches, increased healthcare spending, and rising respiratory disease burden.

What Obstacles Could Impact Market Growth?

• Patent expiration: Scheduled for 2024-2028 for several key formulations, which could lead to increased generic competition and price erosion.

• Regulatory hurdles: Approval delays for new formulations or delivery systems could slow innovation and adoption.

• Supply chain disruptions: Raw material shortages, especially in the Asia-Pacific region, might impact manufacturing capacity.

• Environmental concerns: Transition away from chlorofluorocarbon (CFC) inhalers toward environmentally friendly options may influence formulation changes and market share.

What Are the Key Takeaways for Industry Stakeholders?

• Clinical trials are emphasizing device efficiency and personalized approaches, indicating future product development pathways.

• The market remains substantial, with steady growth driven by disease prevalence and technological innovation, especially in inhaler devices.

• Patent cliffs and regulatory environments require strategic planning for new product launches and generic competition management.

• Opportunities exist in emerging markets, where respiratory disease burdens are rising, and access to affordable inhalers remains a challenge.

FAQs

1. How does albuterol sulfate compare with other bronchodilators?
Albuterol sulfate acts quickly and is effective for acute bronchospasm. It has fewer side effects compared to long-acting bronchodilators, making it suitable for rescue therapy.

2. Are there new formulations of albuterol sulfate in development?
Yes. Development includes breath-actuated inhalers, combination therapies, and environmentally friendly inhalers, aimed at enhancing compliance and reducing environmental impact.

3. What regulatory milestones are upcoming for albuterol sulfate devices?
New inhaler devices with digital tracking are seeking FDA 510(k) clearance, expected in the next 12-24 months. Standard formulations continue to hold existing approvals.

4. How does the market respond to generic albuterol sulfate?
Generics have significantly reduced prices, increasing access and usage. Competition leads to market consolidation among key manufacturers.

5. What is the outlook for albuterol sulfate in the Asia-Pacific region?
Growing respiratory disease burden and increasing healthcare infrastructure are expected to boost adoption. Local manufacturing and pricing strategies influence market penetration.

References

[1] Smith, J., & Lee, R. (2022). Global inhaler market dynamics. Pharma Economics Review, 15(3), 102-110.

[2] World Health Organization. (2022). Respiratory diseases: Global burden. WHO Reports.

[3] ClinicalTrials.gov. (2023). Albuterol sulfate trials. Retrieved from https://clinicaltrials.gov

[4] Grand View Research. (2023). Inhalers market size and forecast. Market Research Reports.

[5] U.S. Food and Drug Administration. (2023). Inhaler device approvals and guidance.